-
Something wrong with this record ?
In vitro metabolism of helenalin and its inhibitory effect on human cytochrome P450 activity
M. Šadibolová, RO. Juvonen, S. Auriola, I. Boušová
Language English Country Germany
Document type Journal Article
NLK
ProQuest Central
from 2002-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2002-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2002-01-01 to 1 year ago
- MeSH
- Species Specificity MeSH
- Inhibitory Concentration 50 MeSH
- Cytochrome P-450 Enzyme Inhibitors administration & dosage metabolism pharmacology MeSH
- Microsomes, Liver metabolism MeSH
- Rats MeSH
- Humans MeSH
- NADP metabolism MeSH
- Rats, Wistar MeSH
- Sesquiterpenes, Guaiane administration & dosage metabolism pharmacology MeSH
- Cytochrome P-450 Enzyme System drug effects metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Sesquiterpene lactone helenalin is used as an antiphlogistic in European and Chinese folk medicine. The pharmacological activities of helenalin have been extensively investigated, yet insufficient information exists about its metabolic properties. The objectives of the present study were (1) to investigate the in vitro NADPH-dependent metabolism of helenalin (5 and 100 μM) using human and rat liver microsomes and liver cytosol, (2) to elucidate the role of human cytochrome P450 (CYP) enzymes in its oxidative metabolism, and (3) to study the inhibition of human CYPs by helenalin. Five oxidative metabolites were detected in NADPH-dependent human and rat liver microsomal incubations, while two reduced metabolites were detected only in NADPH-dependent human microsomal and cytosolic incubations. In human liver microsomes, the main oxidative metabolite was 14-hydroxyhelenalin, and in rat liver microsomes 9-hydroxyhelenalin. The overall oxidation of helenalin was several times more efficient in rat than in human liver microsomes. In humans, CYP3A4 and CYP3A5 followed by CYP2B6 were the main enzymes responsible for the hepatic metabolism of helenalin. The extrahepatic CYP2A13 oxidized helenalin most efficiently among CYP enzymes, possessing the Km value of 0.6 μM. Helenalin inhibited CYP3A4 (IC50 = 18.7 μM) and CYP3A5 (IC50 = 62.6 μM), and acted as a mechanism-based inhibitor of CYP2A13 (IC50 = 1.1 μM, KI = 6.7 μM, and kinact = 0.58 ln(%)/min). It may be concluded that the metabolism of helenalin differs between rats and humans, in the latter its oxidation is catalyzed by hepatic CYP2B6, CYP3A4, CYP3A5, and CYP3A7, and extrahepatic CYP2A13.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22010817
- 003
- CZ-PrNML
- 005
- 20221013134504.0
- 007
- ta
- 008
- 220425s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00204-021-03218-6 $2 doi
- 035 __
- $a (PubMed)34989853
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Šadibolová, Michaela, $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic $1 https://orcid.org/0000000255273802 $d 1993- $7 xx0277533
- 245 10
- $a In vitro metabolism of helenalin and its inhibitory effect on human cytochrome P450 activity / $c M. Šadibolová, RO. Juvonen, S. Auriola, I. Boušová
- 520 9_
- $a Sesquiterpene lactone helenalin is used as an antiphlogistic in European and Chinese folk medicine. The pharmacological activities of helenalin have been extensively investigated, yet insufficient information exists about its metabolic properties. The objectives of the present study were (1) to investigate the in vitro NADPH-dependent metabolism of helenalin (5 and 100 μM) using human and rat liver microsomes and liver cytosol, (2) to elucidate the role of human cytochrome P450 (CYP) enzymes in its oxidative metabolism, and (3) to study the inhibition of human CYPs by helenalin. Five oxidative metabolites were detected in NADPH-dependent human and rat liver microsomal incubations, while two reduced metabolites were detected only in NADPH-dependent human microsomal and cytosolic incubations. In human liver microsomes, the main oxidative metabolite was 14-hydroxyhelenalin, and in rat liver microsomes 9-hydroxyhelenalin. The overall oxidation of helenalin was several times more efficient in rat than in human liver microsomes. In humans, CYP3A4 and CYP3A5 followed by CYP2B6 were the main enzymes responsible for the hepatic metabolism of helenalin. The extrahepatic CYP2A13 oxidized helenalin most efficiently among CYP enzymes, possessing the Km value of 0.6 μM. Helenalin inhibited CYP3A4 (IC50 = 18.7 μM) and CYP3A5 (IC50 = 62.6 μM), and acted as a mechanism-based inhibitor of CYP2A13 (IC50 = 1.1 μM, KI = 6.7 μM, and kinact = 0.58 ln(%)/min). It may be concluded that the metabolism of helenalin differs between rats and humans, in the latter its oxidation is catalyzed by hepatic CYP2B6, CYP3A4, CYP3A5, and CYP3A7, and extrahepatic CYP2A13.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a inhibitory cytochromu P450 $x aplikace a dávkování $x metabolismus $x farmakologie $7 D065607
- 650 _2
- $a systém (enzymů) cytochromů P-450 $x účinky léků $x metabolismus $7 D003577
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibiční koncentrace 50 $7 D020128
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a jaterní mikrozomy $x metabolismus $7 D008862
- 650 _2
- $a NADP $x metabolismus $7 D009249
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a seskviterpeny guajanové $x aplikace a dávkování $x metabolismus $x farmakologie $7 D045789
- 650 _2
- $a druhová specificita $7 D013045
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Juvonen, Risto O $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland $1 https://orcid.org/0000000192407673
- 700 1_
- $a Auriola, Seppo $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland $1 https://orcid.org/0000000245801034
- 700 1_
- $a Boušová, Iva $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic. Iva.Bousova@faf.cuni.cz $1 https://orcid.org/000000032863717X $7 stk2007405423
- 773 0_
- $w MED00009265 $t Archives of toxicology $x 1432-0738 $g Roč. 96, č. 3 (2022), s. 793-808
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34989853 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20221013134458 $b ABA008
- 999 __
- $a ok $b bmc $g 1788776 $s 1162015
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 96 $c 3 $d 793-808 $e 20220106 $i 1432-0738 $m Archives of toxicology $n Arch Toxicol $x MED00009265
- LZP __
- $a Pubmed-20220425